Innovation America Innovation America Accelerating the growth of the GLOBAL entrepreneurial innovation economy
Founded by Rich Bendis

NewImage

The big deal about the just-completed J.P. Morgan (JPM) 38th Healthcare Conference had little to do with big M&A deals, because there weren’t any. This time last year, the $74-billion Bristol-Myers Squibb acquisition of Celgene was announced, as was Eli Lilly’s takeover of Loxo Oncology for $8 billion.

There were no such blockbusters this year, though there was an interesting potentially up-to-$2 billion-plus collaboration: MorphoSys outlicensed ex-U.S. commercialization rights to its anti-CD19 Fc-engineered antibody tafasitamab to Incyte, with the companies agreeing to co-commercialize the B cell malignancy candidate Stateside.

Image: A dearth of deals, Illumina’s double launches, and the usual crowds marked the 38th J.P. Morgan 38th Conference. - https://www.genengnews.com